What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide Regulation FD disclosure. It informs the public that the company's officers will be meeting with securities analysts and investors and confirms the company's ability to meet its previously issued earnings guidance, with a specific adjustment for a one-time gain.

What is the 'non-recurring benefit' mentioned in the filing?

The non-recurring benefit is approximately $0.11 per diluted share. This amount is being excluded from the confirmation of earnings expectations and arises from the resolution of a legal case involving the estate of Esther Louise Dardinger against Anthem Blue Cross and Blue Shield.

What are the risks highlighted by the company?

The company outlines several risks and uncertainties that could impact future performance. These include trends in healthcare costs and utilization, premium rate increases, competitor actions, government regulation, acquisition integration (specifically mentioning the Trigon Healthcare, Inc. acquisition), new drug/technology impacts, financial strength rating downgrades, debt levels, litigation, and general economic downturns.

Should investors rely heavily on the forward-looking statements provided?

The company explicitly cautions investors against placing undue reliance on these forward-looking statements. They are subject to significant risks and uncertainties, and actual results could differ materially. Furthermore, the company states it has no obligation to update these statements to reflect events occurring after the filing date.

ELV 8-K SEC Disclosure — Mar 24, 2003

Summary

This 8-K filing from Elevance Health, Inc. (then Anthem, Inc.) on March 24, 2003, primarily serves as a Regulation FD disclosure. The company announced that its officers were scheduled to meet with securities analysts and investors. A key takeaway for investors is the confirmation of the company's ability to meet previously stated earnings expectations from a February 3, 2003, press release and conference call. This confirmation, however, excludes a non-recurring benefit of approximately $0.11 per diluted share. This benefit stemmed from the resolution of a specific legal matter (Robert Lee Dardinger, Executor of the Estate of Esther Louise Dardinger v. Anthem Blue Cross and Blue Shield, et al.). Investors should note that the filing also reiterates forward-looking statements and includes a comprehensive list of risks and uncertainties that could materially affect actual results. These risks range from healthcare cost trends and regulatory changes to acquisition integration and general economic conditions. The company cautioned against undue reliance on these forward-looking statements, emphasizing that they speak only as of the filing date and that Anthem does not undertake to revise them.

Key Highlights

1Company officers to meet with securities analysts and investors during the week of March 24, 2003.
2Confirmation of ability to meet previously stated earnings expectations (from Feb 3, 2003, press release/call).
3Exclusion of a non-recurring benefit of approximately $0.11 per diluted share from earnings confirmation.
4The non-recurring benefit is related to the resolution of a legal case: Dardinger v. Anthem Blue Cross and Blue Shield, et al.
5Reiteration of forward-looking statements and associated risks and uncertainties.
6Caution to investors regarding reliance on forward-looking statements due to inherent uncertainties.
7Company has undertaken no obligation to update forward-looking statements post-filing date.

Elevance Health, Inc. 8-K Report (Mar 24, 2003)

Summary

Key Highlights

Frequently Asked Questions